Corbus Pharmaceuticals Holdings, Inc. announced that an abstract highlighting pre-clinical data for CRB-601, its av8 blocking antibody, has been accepted for oral presentation in the main program of the New York Academy of Sciences' 2023 Frontiers in Cancer Immunotherapy meeting, taking place in New York, NY May 2-4, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.88 USD | +0.90% | +2.84% | +626.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+626.49% | 469M | |
+16.13% | 122B | |
+19.65% | 113B | |
+17.73% | 26.49B | |
-23.84% | 19.4B | |
-19.37% | 16.24B | |
-19.28% | 15.4B | |
-45.95% | 15.15B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. to Present Latest Pre-Clinical Data on CRB-601 Av8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting